Items where Author is "Maertens, Johan A."

2018

Schoemans, Helene M. and Goris, Kathy and Van Durm, Raf and Fieuws, Steffen and De Geest, Sabina and Pavletic, Steven Z. and Im, Annie and Wolff, Daniel and Lee, Stephanie J. and Greinix, Hildegard and Duarte, Rafael F. and Poiré, Xavier and Selleslag, Dominik and Lewalle, Philippe and Kerre, Tessa and Graux, Carlos and Baron, Frédéric and Maertens, Johan A. and Dobbels, Fabienne and Ebmt Transplantation Complications Working party, . (2018) The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial. Haematologica, 103 (10). pp. 1698-1707.

2011

Socié, Gérard and Schmoor, Claudia and Bethge, Wolfgang A. and Ottinger, Hellmut D. and Stelljes, Matthias and Zander, Axel R. and Volin, Liisa and Ruutu, Tapani and Heim, Dominik A. and Schwerdtfeger, Rainer and Kolbe, Karin and Mayer, Jiri and Maertens, Johan A. and Linkesch, Werner and Holler, Ernst and Koza, Vladimir and Bornhäuser, Martin and Einsele, Hermann and Kolb, Hans-Jochem and Bertz, Hartmut and Egger, Matthias and Grishina, Olga and Finke, Jürgen and ATG-Fresenius Trial Group, . (2011) Chronic graft-versus-host disease : long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood, Vol. 117, H. 23. pp. 6375-6382.

2009

Finke, Jürgen and Bethge, Wolfgang A. and Schmoor, Claudia and Ottinger, Hellmut D. and Stelljes, Matthias and Zander, Axel R. and Volin, Liisa and Ruutu, Tapani and Heim, Dominik A. and Schwerdtfeger, Rainer and Kolbe, Karin and Mayer, Jiri and Maertens, Johan A. and Linkesch, Werner and Holler, Ernst and Koza, Vladimir and Bornhäuser, Martin and Einsele, Hermann and Kolb, Hans-Jochem and Bertz, Hartmut and Egger, Matthias and Grishina, Olga and Socié, Gérard. (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors : a randomised, open-label, multicentre phase 3 trial. The Lancet oncology, Vol. 10. pp. 855-864.